Esketamine nasal spray for treatment‐resistant depression
Prescriber May 1, 2020 DOI: 10.1002/psb.1845 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Adults with treatment-resistant major depression |
| Topics | Depression Esketamine |
| Citations | 1 |
| Key findings | Esketamine nasal spray (Spravato) is a new adjunctive therapy for treatment-resistant major depression, with its efficacy and adverse effects discussed based on clinical trial data. |
Abstract
A nasal spray formulation of esketamine (Spravato) was licensed as adjunctive therapy for the management of adults with treatment‐resistant major depression in December. This article discusses the properties, clinical trial efficacy and adverse effects of this new treatment option.